Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MPL | P40238 | 14/20 | 0.51 |
| ▸ | ADORA3 | P0DMS8 | 4/20 | 0.41 |
| ▸ | ITGB2 | P05107 | 1/20 | 0.39 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.39 |
| ▸ | ITGAL | P20701 | 1/20 | 0.39 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17386604 | 1.00 | MPL (0.51) | MPLADORA3ITGB2ICAM1ITGAL | |
| SCHEMBL17400637 | 1.00 | MPL (0.51) | MPLADORA3ITGB2ICAM1ITGAL | |
| Hydrochloric Acid SCHEMBL30938547 | 0.99 | MPL (0.50) | MPLADORA3ITGB2ICAM1ITGAL | |
| SCHEMBL17400681 | 0.98 | MPL (0.50) | MPLADORA3ITGB2ICAM1ITGAL | |
| SCHEMBL17386783 | 0.95 | MPL (0.50) | MPLADORA3ITGB2ICAM1ITGAL | |
| SCHEMBL17400565 | 0.95 | MPL (0.51) | MPLADORA3S1PR1 | |
| SCHEMBL21301173 | 0.95 | MPL (0.49) | MPLADORA3ITGB2ICAM1ITGAL | |
| SCHEMBL17400638 | 0.95 | MPL (0.49) | MPLADORA3ITGB2ICAM1ITGAL | |
| SCHEMBL17400510 | 0.95 | MPL (0.49) | MPLADORA3ITGB2ICAM1ITGAL | |
| SCHEMBL18470823 | 0.94 | MPL (0.48) | MPLADORA3ITGB2ICAM1ITGAL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2963036-B1 | 2-ACYLAMINOTHIAZOLE DERIVATIVE AND SALT THEREOF | ASTELLAS PHARMA INC (JP) | 2019-08-28 | — | — | EP | disclosed |
| US-9562044-B2 | 2-acylaminothiazole derivative or salt thereof | ASTELLAS PHARMA INC. (JP) | 2017-02-07 | — | — | US | disclosed |
| US-20160002218-A1 | 2-ACYLAMINOTHIAZOLE DERIVATIVE OR SALT THEREOF | ASTELLAS PHARMA INC. (JP) | 2016-01-07 | — | — | US | disclosed |
| EP-2963036-A1 | 2-ACYLAMINOTHIAZOLE DERIVATIVE AND SALT THEREOF | Astellas Pharma Inc. (JP) | 2016-01-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160002218-A1 | 2-ACYLAMINOTHIAZOLE DERIVATIVE OR SALT THEREOF | CHRM3, CHRM2, CHRM5 | MPL 3292/4885ADORA3 56/4885ITGB2 1965/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.